-+ 0.00%
-+ 0.00%
-+ 0.00%
Sphene Capital Reiterates Buy on AlzChem With EUR 198.40 Price Target
Share
Listen to the news
Sphene Capital Reiterates Buy on AlzChem With EUR 198.40 Price Target
  • Sphene Capital reiterated its Buy rating on AlzChem on Nov. 16, 2026, maintaining a EUR 198.40 price target.
  • The 24-month target implies 42.5% upside, based on the research firm's three-stage discounted cash flow model.
  • Supervisory board clearance advances the roughly USD 150 million Bushy Park nitroguanidine plant project to supply the US military.
  • A committed USD 150 million nonrepayable US government grant will largely fund the project, limiting the strain on internal liquidity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzChem Group AG published the original content used to generate this news brief via EQS News (Ref. ID: rc_27538) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending